ReviewDermatologic therapy2022

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.

Huiying Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.